Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
RESEARCH TOOLSreports
Neuren Pharmaceuticals Limited (NEU) Share Price & Analysis
69 Followers
NEU Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$10.02 - AU$25.95
Previous CloseAU$19.67
Volume97.81K
Average Volume (3M)514.07K
Market Cap
AU$2.56B
Enterprise ValueAU$2.52B
Total Cash (Recent Filing)AU$40.18M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)15.9
Beta0.73
Next Earnings
Aug 27, 2024EPS Estimate
AU$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.24
Shares OutstandingN/A
10 Day Avg. Volume173,887
30 Day Avg. Volume514,065
Standard Deviation0.21
R-Squared0.20
Alpha0.00315
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$27.97Price Target Upside47.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Neuren Pharmaceuticals Limited News
PremiumCompany Announcements
Neuren Pharmaceuticals Seeks New Security Quotation
Options Prices
Currently, No data available
---
Ownership Overview
34.29% Insiders
2.50% Mutual Funds
2.79% Other Institutional Investors
60.41% Public Companies and
Individual Investors
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$10.02 and its highest was AU$25.95 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Currently, no data Available
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Aug 27, 2024 which is in 129 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Feb 29, 2024. The company reported AU$0.86 earnings per share for the quarter, missing the consensus estimate of AU$0.982 by -AU$0.122.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is AU$0.2.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 129,945,680 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.86 in its last earnings report, missing expectations of AU$0.982. Following the earnings report the stock price went up 1.097%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
---
Neuren Pharmaceuticals Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$27.97 (47.58% Upside)
AU$27.97 (47.58% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 94%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.66%
12-Months-Change
Fundamentals
Return on Equity
123.16%
Trailing 12-Months
Asset Growth
476.67%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.
---
NEU Company Deck
---
NEU Earnings Call
Q4 2024
0:00 / 0:00
---
NEU Stock 12 Months Forecast
Average Price Target
AU$27.97
▲(47.58% Upside)
Technical Analysis
Minerva Neurosciences
―
Anavex Life Sciences
―
Cytokinetics
―
Insmed
―
Neuren Pharmaceuticals Limited
―
Best Analysts Covering NEU
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+43.05%
reiterated a buy rating 2 months ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +43.05% per trade.
---